« Return to News | Ethics/Regulatory

Pearl IRB, Trafalgar Ethics Board join forces

Thursday, July 28, 2011 11:50 AM

With the multi-center global clinical trials trend continuing to grow, the U.S. and Canada accounted for 60.5% of sponsored trials in 2010. To deliver integrated U.S.-Canada study reviews, Pearl IRB, based in Indianapolis, and Toronto-based Trafalgar Ethics Board have joined forces.

Clinical trials are often delayed for many reasons, including contract negotiations, budgeting issues and IRB reviews. “We strive to decrease site review times by integrating our processes to provide parallel U.S. and Canadian site reviews,” said Diana Caldwell, president and CEO of Pearl IRB. “Additionally, we will partner to offer additional services including medical writing, GCP/ICH assistance and site training, all of which reach across Canada and the U.S. now.”

“Both our Canadian clients and U.S.-based sponsors are demanding higher quality and increased efficiencies in the global regulatory oversight of their clinical trials,” added Ali Thompson, director of Trafalgar Ethics Board. “By working together to provide seamless U.S.-Canada IRB reviews, we eliminate much duplication and help streamline work for our clients.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.